Balance Sheet
Cash Flow Statement
Cash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Alaunos Therapeutics (TCRT) Cash from Financing Activities (2016 - 2023)

Alaunos Therapeutics (TCRT) has disclosed Cash from Financing Activities for 12 consecutive years, with -$12.0 million as the latest value for Q2 2023.

  • For the quarter ending Q2 2023, Cash from Financing Activities changed N/A year-over-year to -$12.0 million, compared with a TTM value of -$12.0 million through Mar 2024, down 5832.06%, and an annual FY2023 reading of -$18.1 million, down 384.88% over the prior year.
  • Cash from Financing Activities was -$12.0 million for Q2 2023 at Alaunos Therapeutics, down from -$6.2 million in the prior quarter.
  • Across five years, Cash from Financing Activities topped out at $101.7 million in Q1 2020 and bottomed at -$12.0 million in Q2 2023.
  • Average Cash from Financing Activities over 4 years is $9.7 million, with a median of $23000.0 recorded in 2020.
  • Peak annual rise in Cash from Financing Activities hit 92218.52% in 2021, while the deepest fall reached 146.5% in 2021.
  • Year by year, Cash from Financing Activities stood at $400000.0 in 2020, then crashed by 146.5% to -$186000.0 in 2021, then soared by 4655.91% to $8.5 million in 2022, then plummeted by 241.37% to -$12.0 million in 2023.
  • Business Quant data shows Cash from Financing Activities for TCRT at -$12.0 million in Q2 2023, -$6.2 million in Q1 2023, and $8.5 million in Q4 2022.